| Document |
Document Title |
|
WO/2023/138341A9 |
The present application relates to the technical field of medicine synthesis, and in particular to a synthesis method for ertapenem sodium. The present application provides a synthesis method for ertapenem sodium, comprising the followin...
|
|
WO/2023/024310A1 |
Provided are a new crystalline form of ertapenem sodium and a preparation method therefor. The powder X-ray diffraction diagram of the new crystalline form of ertapenem sodium contains 27 principal characteristic peaks. The ertapenem sod...
|
|
WO/2022/239872A1 |
The present invention provides: a compound represented by formula (I), formula (II), or formula (IV), or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition that is to be used for inhibiting metallo-β-lactamase ...
|
|
WO/2022/223390A1 |
The present invention relates to a method of synthesizing a photolytically degradable compound, which method comprises identifying a biologically active target molecule comprising substituted aromatic group(s); providing a starting mater...
|
|
WO/2022/130352A1 |
Present invention relates to compounds of general formula (I), their tautomeric forms, stereoisomers, pharmaceutically acceptable salts and pharmaceutical composition containing them. Invention also relates to process for the preparation...
|
|
WO/2021/227507A1 |
The present invention relates to a method for preparing an imipenem active pharmaceutical ingredient, the method comprising the following steps: 1) dissolving crude imipenem in water at 5-25°C to obtain an aqueous solution of imipenem; ...
|
|
WO/2021/105512A1 |
This invention relates to probes for the detection of β-lactamase-type enzymatic activity. In particular, the invention relates to novel fluorogenic substrates for detecting the presence of a catalytically active β-lactamase and a dete...
|
|
WO/2021/101620A1 |
The present disclosure provides broad-spectrum carbapenem derivatives and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such derivatives and/or compositions.
|
|
WO/2021/072622A1 |
Provided are a continuous post-treatment method and device for a penem compound. The method comprises the following steps: S1, performing continuous extraction on a reaction crude product of a penem compound to obtain an extraction heavy...
|
|
WO/2021/055637A1 |
Provided herein are compounds, such as compounds for use in treating cancer. Also provided are methods of treating cancer, including treatment resistant cancer or cancer associated with a hypoxic tumor.
|
|
WO/2019/232053A1 |
The present disclosure provides broad-spectrum carbapenem derivatives and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such derivatives and/or compositions.
|
|
WO/2018/130158A9 |
Disclosed in the present invention is a carbapenem antibiotic-tolerant pathogenic bacterium fluorescent probe with a structural general formula as represented by general formula I. The synthesis method for the fluorescent probe comprises...
|
|
WO/2018/145089A1 |
The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxi...
|
|
WO/2018/010974A1 |
201600080 17 Process for preparing a carbapenem Abstract Process for preparing a carbapenem or precursors thereof (I) by cleaving one or more protecting groups of a substance (II) 5 comprising the steps of: a) hydrogenating with hydrogen...
|
|
WO/2017/132321A1 |
New antimicrobials targeting L,D-transpeptidases, non-classical cysteine peptidases, have been developed and their unique chemical structures identified. Carbapenems and penems of the present invention are unique among β-lactams as they...
|
|
WO/2017/008034A1 |
The present disclosure encompasses antibacterial compositions and methods of treating bacterial infections caused by resistant bacteria.
|
|
WO/2016/148439A2 |
The present invention relates to a method of preparing a crystalline doripenem. According to the present invention, it is possible to prepare the crystalline doripenem in a simple way without additional special equipment. In addition, al...
|
|
WO/2015/167148A1 |
The present invention relates to a novel crystal of doripenem, a solvate thereof, and a preparation method therefor. More specifically, the novel crystal is an anhydrous crystal of doripenem, and the present invention relates to a method...
|
|
WO/2015/145161A1 |
The present invention provides a process for the preparation of a carbapenem, said process comprising the step of treating a solution of a protected carbapenemwith hydrogen gas in the presence of a heterogeneous catalystto form the carba...
|
|
WO/2015/078218A1 |
The present invention discloses a polymer containing a carboxyl group, a method for preparing same and a use thereof, and a method for preparing a supported catalyst and a penem antibiotic intermediate. The polymer is made by polymerizin...
|
|
WO/2014/144285A1 |
The present invention provides novel derivative of β-lactam antibiotics, such as meropenem. The inventive compounds include compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, ta...
|
|
WO/2014/097221A1 |
The present invention relates to a process for the purification of biapenem.
|
|
WO/2014/094659A1 |
Disclosed is a process for preparation of meropenem trihydrate crystals, comprising: 1) dissolving crude meropenem in an alkali solution, thus forming a saturated solution of meropenem; 2) adding activated carbon into the saturated solut...
|
|
WO/2014/082226A1 |
The present invention relates a purification method of ertapenem sodium. Specifically, disclosed is a preparation method of low-chroma ertapenem sodium, which comprises steps of: providing an aqueous solution comprising a raw material of...
|
|
WO/2014/057079A1 |
The present invention relates to the preparation of compounds, in particular to the preparation of compounds which may be used as intermediates for the preparation of antibiotics, preferably carbapenem antibiotics, more preferably ertape...
|
|
WO/2014/019282A1 |
Disclosed in the present invention is a bulk drug of meropenem, characterized in that the meropenem content in the bulk drug is 98.5%~101.0% based on the anhydrous substances; the impurities A and B in the related substances of the bulk ...
|
|
WO/2013/157583A1 |
The purpose of the invention is to provide a compound having excellent antimicrobial activity and oral absorbability, and comprising a crystal form having storage stability that permits practical use as a pharmaceutical ingredient. The i...
|
|
WO/2013/150550A2 |
The present invention provides an improved process for the preparation Ertapenem monosodium of formula (I) having purity greater than 98.5% and having pharmaceutically acceptable level of palladium and residual solvent. (I)
|
|
WO/2013/143266A1 |
The present invention provides a doripenem intermediate compound shown by formula (XIV), wherein PNB is p-nitrobenzyl, and HX is an acid; and when HX is a monoacid, n = 1; and when HX is a polyacid, n = 2. The present invention also prov...
|
|
WO/2013/121279A2 |
The present invention relates to a novel process for the preparation of Ertapenem of formula (I) or salt thereof.
|
|
WO/2013/067878A1 |
Disclosed are an Ertapenem sodium crystal and preparation method thereof, the Ertapenem sodium crystal has a powder X-ray diffraction spectrum as shown in Fig. 1. The Ertapenem sodium crystal is of low residual solvent content and high s...
|
|
WO/2013/068910A1 |
The present invention relates to a process for the preparation of polymorphs of doripenem.
|
|
WO/2013/034087A1 |
Disclosed are a doripenem hydrate crystal and preparation method therefor. The X-ray diffraction spectrogram of the crystal powder is basically as represented in figure 1, and the measured water content is 4.4 to 5.5%. The doripenem hydr...
|
|
WO/2013/029293A1 |
Provided is a method for preparing ertapenem sodium. In the method provided by the invention, ertapenem sodium is prepared by directly catalytic hydrogenation of an undried ertapenem intermediate or by catalytic hydrogenation of the erta...
|
|
WO/2012/139414A1 |
Disclosed is a method for preparing carbapenem antibiotics, pharmaceutically acceptable salts or hydrates thereof. In particular, disclosed is a method for preparing carbapenem antibiotics, pharmaceutically acceptable salts or hydrates t...
|
|
WO/2012/139424A1 |
Disclosed are two crystalline forms of tebipenem, preparation methods and uses thereof in the preparation of medicines. The crystalline forms of tebipenem have good stability, fine color (white), high purity, low heavy metal residue and ...
|
|
WO/2012/112061A1 |
The subject of the present invention is a method of the preparation of compounds containing the core skeleton of carbapenem antibiotics, novel intermediate compounds used in this method, a method of the preparation of the intermediate co...
|
|
WO/2012/097471A1 |
Provided is a preparation method of compound shown by formula (I), which comprises the following steps: in the presence of alkali, reacting compound of formula (III) with compound of formula (IV) in organic solvents to obtain compound of...
|
|
WO/2012/089058A1 |
Provided is a crystalline form E of ertapenem sodium. Further provided is a method for preparing a crystalline form E of ertapenem sodium, characterized by using an aqueous ertapenem sodium solution at a low concentration as a raw materi...
|
|
WO/2012/079504A1 |
Disclosed is a process for preparing Tebipenem Pivoxil and analogues thereof. The process uses a carbapenem compound salt of the formula II as a raw material to obtain a carbapenem compound ester of the formula I, wherein the carbapenem ...
|
|
WO/2012/079289A1 |
The present invention relates to an amorphous powder, a solvate, and a polymorph of a carbapenem derivative (4R,55,6S)3-[(3S,5S)-5-[(furan-2-ylmethyl)amino-formyl]3-pyr
rolidine]thio-6-[(R)-1-hydroxyethyl]4-methyl-7-oxo-1-oxabicy
clo[3.2...
|
|
WO/2012/066492A1 |
The present invention relates to processes for the preparation of carbapenem antibiotic compositions, involving the preparation of the compound of formula II from a compound of formula I and a composition comprising the compound of formu...
|
|
WO/2012/062035A1 |
Disclosed is a synthesis method for meropenem, the reaction chain whereof is represented below: [Formula IV] → [Formula V] → [Formula II] [Formula VI] → [Formula III] – Wittig → [Formula VII] → [Formula VIII] → [Formula I] ...
|
|
WO/2012/052978A1 |
The present invention relates to a process for the preparation of pure meropenem trihydrate.
|
|
WO/2012/038979A2 |
The present invention relates to a novel process for the preparation of 1 β- methylcarbapenem antibiotic, Ertapenem of formula I. The process comprises isolation of monoprotected Ertapenem acid or its monosodium salt and further deprote...
|
|
WO/2012/027951A1 |
The invention relates to an intermediate used for preparation of imipenem medicine, a preparation method and use thereof. The said intermediate is shown in the structure of formula (I), wherein R1 is C1- C3 lower alkyl, nitryl, halogen, ...
|
|
WO/2012/003955A1 |
Chromogenic or fluorescent carbapenems according to formula I, wherein Ar is a mono or disubstituted carbocyclic aromatic group or an optionally mono or disubstituted heterocyclic aromatic group, are useful compounds for the detection of...
|
|
WO/2011/160020A2 |
The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The inventio...
|
|
WO/2011/150679A1 |
Crystalline form of carbapenem derivative shown as formula (I) or its hydrates characterized by an X-ray powder diffraction pattern given in the specification are disclosed. The preparation methods and uses of the crystalline form of car...
|
|
WO/2011/143935A1 |
Disclosed are a crystalline of carbapenem derivative represented by formula (I) (4R,5S,6S)-3-[(3S,5S)-5-[(4-aminosulfonylphen-1-yl)methyl)am
inoformyl]-3-pyrrolidinyl]thio-6-[(R)-1-hydroxyethyl]-4-meth
yl-7-oxo-1-azabicyclo[3.2.0]hept-2-...
|
